Get the Stockscreener App
33.99
0.67%
-0.23
After Hours:
33.99
Immunocore Holdings Plc Adr stock is traded at $33.99, with a volume of 309.27K.
It is down -0.67% in the last 24 hours and down -7.23% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$34.22
Open:
$34.26
24h Volume:
309.27K
Relative Volume:
1.06
Market Cap:
$1.71B
Revenue:
$357.71M
Net Income/Loss:
$-20.10M
P/E Ratio:
-85.86
EPS:
-0.3959
Net Cash Flow:
$28.67M
1W Performance:
-5.40%
1M Performance:
-7.23%
6M Performance:
+38.57%
1Y Performance:
+11.19%
1-Day Range:
$33.93
$35.02
1-Week Range:
$33.79
$37.00
52-Week Range:
$23.15
$39.33
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
33.99 | 1.72B | 357.71M | -20.10M | 28.67M | -0.3959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Resumed | Guggenheim | Neutral |
| Aug-25-25 | Resumed | Jefferies | Buy |
| May-27-25 | Initiated | Deutsche Bank | Buy |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stocks Showing Improved Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
Goldman Sachs Group Inc. Sells 4,782 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - Defense World
Embracer Group AB (publ) (LON:0GFE) Shares Up 3% – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Insider Sells $803,716.44 in Stock - MarketBeat
Immunocore (NASDAQ:IMCR) Now Covered by Analysts at Guggenheim - Defense World
Vericel (NASDAQ:VCEL) Shares Gap Down on Analyst Downgrade - Defense World
Monument Circle Acquisition (OTCMKTS:MONCU) Shares Down 0.3% – What’s Next? - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.89 Average Price Target from Analysts - MarketBeat
Green Energy Stocks Worth Watching – September 12th - Defense World
Cubist Systematic Strategies LLC Reduces Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Hold” by Analysts - Defense World
Banque Transatlantique SA Acquires Shares of 10,150 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Baker BROS. Advisors LP Has $68.91 Million Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Stellar AfricaGold (CVE:SPX) Shares Up 25.8% – What’s Next? - Defense World
Frazier Life Sciences Management L.P. Has $8.94 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects - Investing.com India
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects By Investing.com - Investing.com South Africa
Immunocore Holdings plc ADR (NASDAQ: IMCR) Rises 9.33% In Recent Trading, What’s Next? - stocksregister.com
Emergent Biosolutions Inc. $EBS Holdings Trimmed by Invesco Ltd. - Defense World
Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Earnings call transcript: Immunocore Q2 2025 beats revenue forecast - Investing.com
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.00 Consensus Price Target from Brokerages - Defense World
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - sharewise.com
Immunocore (IMCR) Q2 Revenue Jumps 30% - The Motley Fool
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - sharewise.com
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - sharewise.com
Immunocore stock price target raised to $36 from $33 at Mizuho - Investing.com
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Immunocore Holdings ADR Earns IBD Rating Upgrade - Investor's Business Daily
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - The Globe and Mail
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunocore Holdings Plc Adr Stock (IMCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Sep 30 '25 |
Sale |
35.23 |
61,849 |
2,178,940 |
0 |
| Berman David M | HEAD OF R&D |
Sep 12 '25 |
Option Exercise |
17.46 |
22,532 |
393,409 |
22,532 |
| Berman David M | HEAD OF R&D |
Sep 15 '25 |
Option Exercise |
17.46 |
200 |
3,492 |
200 |
| Berman David M | HEAD OF R&D |
Sep 12 '25 |
Sale |
35.67 |
22,532 |
803,699 |
0 |
| Berman David M | HEAD OF R&D |
Sep 15 '25 |
Sale |
35.01 |
200 |
7,002 |
0 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Option Exercise |
17.46 |
31,338 |
547,161 |
31,338 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Option Exercise |
17.46 |
19,081 |
333,154 |
19,081 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Sale |
36.14 |
31,338 |
1,132,709 |
0 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Sale |
36.28 |
19,081 |
692,259 |
0 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):